Table 1.
General clinical characteristics of controls and Fabry patients
| Variables | Control (n=20) | Fabry (n=48) | P-value control vs Fabry | Fabry untreated (n=15) | P-value control vs Fabry untreated | Fabry treated (n=33) | P-value control vs Fabry treated | P-value Fabry untreated vs treated |
|---|---|---|---|---|---|---|---|---|
| Age (years) | 35 (26–53) | 36 (18–88) | NS | 24 (18–57) | NS | 38 (18–88) | NS | NS |
| Gender, males [n(%)] | 6 (30) | 15 (33) | NS | 3 (20) | NP | 12 (36) | NS | NS |
| eGFR (CKD-EPI) (mL/min/1.73 m2) | 111.45 (93.6–125.8) | 105.95 (40.7–143.3) | NS | 115 (48.8–137.8) | NS | 101.6 (18.2–156) | NS | NS |
| UPCR (g/g) | 0.04 (0.03–0.10) | 0.08 (0.3–2.45) | 0.002 | 0.07 (0.03–1.10) | 0.0093 | 0.08 (0.04–2.45) | <0.001 | NS |
| Podocyturia/creatininuria (cells/g) | 0 (0–0.14) | 0.15 (0–1.93) | <0.001 | 0.15 (0–0.36) | <0.001 | 0.14 (0–1.93) | <0.001 | NS |
| Colocalized podocytes synaptopodin+podocalyxin [n/N (%)] | 8/8 (100) | 13/48 (27) | <0.001 | 2 (13) | NP | 11 (33) | <0.001 | NP |
| Lyso-Gb3 (nmol/L) | 0.4 (0.3–0.5) | 5.2 (2.9–12) | <0.0001 | 5 (3.2–8) | NP | 6.4 (2.9–12) | <0.001 | NS |
Data are presented as median (range) unless otherwise indicated.
NS, non-significant; NP, not performed (due to low number of cases).